05/16/2026
Healthcare providers are reviewing an interesting local-contact approach for anterior nosebleeds:
Could prescriber-directed Compounded Tranexamic Acid 7.5% in BASSAGEL® (TXA) be applied to a Nampon™ and then used as a topical nasal contact / packing option for selected patients?
The clinical logic is straightforward.
Nampons™ are designed for anterior nosebleeds, helping provide localized contact, absorption, pressure, and clot-supporting surface activity inside the affected nostril.
TXA is an antifibrinolytic. In topical bleeding management, the goal is not to create a new clot throughout the body, but to help stabilize clot formation where the medication is placed. BASSAGEL® may also help keep TXA in contact with the intended surface while local pressure or packing is used.
That creates a potentially complementary concept:
Nampon™ = local contact, absorption, pressure, and physical clot support
TXA = prescriber-directed compounded topical antifibrinolytic support at the bleeding surface
This is not a universal recommendation, and it is not a substitute for emergency evaluation. But for healthcare providers managing selected anterior epistaxis patients — including recurrent nosebleeds, procedure-related bleeding, or patients where local therapy is appropriate — the TXA/BASSAGEL® + Nampon™ concept may be worth thoughtful clinical review.
As always, patient selection matters. Severe nosebleeds, posterior bleeding concerns, trauma, uncontrolled bleeding, or bleeding lasting more than 15 minutes should be evaluated medically. Compounded TXA/BASSAGEL® use should be patient-specific, prescription-based, and directed by the treating healthcare provider.
Compounded medications are not reviewed by FDA for safety or efficacy.
As always, happy to share the formula with any healthcare provider worldwide - TXA is an easy compound to make and has a 180-Day Beyond-Use-Date.
Kingdom Investment Holdings Bassagel
